Belite Bio(BLTE) - 2023 Q4 - Annual Report

Exhibit 99.1 · Enrollment of a pivotal global Phase 3 trial of Tinlarebant in adolescent STGD1 subjects ("DRAGON") has been completed with 104 subjects across 11 countries SAN DIEGO, March 11, 2024 - Belite Bio, Inc (NASDAQ: BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its audited financial results for full-year 2023 ...